July 27, 2022
PAR-22-173 - Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
PAR-22-174 - Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
National Cancer Institute (NCI)
The National Cancer Institute (NCI) will hold a pre-application webinar on August 8, 2022, from 2:00 PM to 3:30 PM Eastern Time for the Funding Opportunity Announcements (FOAs) PAR-22-173 "Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)" and PAR-22-174 "Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)".
NCI staff members involved in managing the new Cancer Prevention and Control Clinical Trials Planning Grant Program will assist potential applicants by explaining the goals and objectives of this initiative and answering questions from attendees. Prospective applicants are encouraged to submit their questions or comments to program staff ([email protected]) in advance of the webinar by August 5, 2022. The webinar will be recorded. A document highlighting frequently asked questions and corresponding answers will be posted to the Division of Cancer Prevention website following the webinar.
Please include "Pre-application webinar for Clinical Trials Planning FOAs: question/comment submission” in the subject line of the email for all question/comment submissions.
Webinar Information:
To join the Webinar, pre-registration is required through Webex at: https://cbiit.webex.com/cbiit/j.php?RGID=r885e29c73cdb14bbbbc8a08ed626f214
Specific Webinar information including the webinar link will be provided upon registration.
Participation in this webinar, although encouraged, is optional and is not required for the submission of an application in response to PAR-22-173 or PAR-22-174.
Brandy Heckman-Stoddard, Ph.D., M.P.H.
Division of Cancer Prevention
National Cancer Institute (NCI)
Telephone: 240-276-7048
Email: [email protected]
and Human Services (HHS)
